StreetAlpha
13F holdings · Q3 2026

Superstring Capital Management

New York, NY · files as Superstring Capital Management LP
Know the moment Superstring Capital Management filesYou follow Superstring Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1931118

Superstring Capital Management reported 35 stocks worth $200M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are COGT (9.6%), AXSM (9.5%) and TRVI (7.1%). Compared with Q2 2026, the fund opened new positions in LEGN, IONS and SGMT, added to COGT, AXSM and TRVI, trimmed GMAB, RVMD and CLDX and sold out of ORIC, PCVX and ONC.

Latest filing: what Superstring Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
12 new14 added9 trimmed9 sold outBought about $79.2M · sold about $29.1M
New 12
See all 12 →
Added 14
See all 14 →
Trimmed 9
See all 9 →
Sold out 9
See all 9 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$200M+26.0% vs last quarter
Stocks held3512 new · 9 sold out
Top 5 weight37.9%fairly concentrated
Turnover54%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
COGT
Cogent Biosciences Inc
$19.1M9.6%597K+254K (+74%)8 of 8
2
AXSM
Axsome Therapeutics Inc
$18.9M9.5%102K+49K (+90%)5 of 8
3
TRVI
Trevi Therapeutics Inc
$14.1M7.1%985K+461K (+88%)4 of 8
4
GMAB
Genmab A/s
$13M6.5%366K−65K (−15%)4 of 8
5
CLYM
Climb Bio Inc
$10.5M5.3%918K+397K (+76%)4 of 8
6
ZLAB
Zai Lab Ltd
$9.6M4.8%363K+207K (+133%)8 of 8
7
ANL
Adlai Nortye Ltd
$9.4M4.7%588K+36K (+7%)3 of 8
8
RVMD
Revolution Medicines Inc
$8.6M4.3%42K−9,269 (−18%)3 of 8
9
CLDX
Celldex Therapeutics Inc
$7.9M3.9%242K−45K (−16%)4 of 8
10
IMVT
Immunovant Inc
$7.5M3.8%222K+14K (+7%)5 of 8
🔒 25 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
ORIC
Oric Pharmaceuticals Inc
$4.4M406K
PCVX
Vaxcyte Inc
$3.9M67K
ONC
Beone Medicines Ltd
$3.5M12K
SION
Sionna Therapeutics Inc
$2.8M63K
ACRS
Aclaris Therapeutics Inc
$1.4M258K

🔒 Free account: see all 9.

Reported value

last 8 quarters
$114MQ4 '24
$83.8MQ1 '25
$80.3MQ2 '25
$102MQ3 '25
$187MQ4 '25
$140MQ1 '26
$158MQ2 '26
$200MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Superstring Capital Management 13F FAQ

What does Superstring Capital Management own?

Superstring Capital Management reported 35 stocks worth $200M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are COGT (9.6%), AXSM (9.5%) and TRVI (7.1%). The table above lists every position in the filing (the top 10 without an account).

What did Superstring Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 12 new positions, 14 added to, 9 trimmed and 9 sold out. New positions include LEGN, IONS and SGMT. It sold all of ORIC, PCVX and ONC.

When will Superstring Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Superstring Capital Management's portfolio worth?

The Q3 2026 filing reports $200M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.